HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib

Publisher： Karger

E-ISSN： 1423-0232|82|3|175-179

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.3, 2012-03, pp. : 175-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite

An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers

By  

Oncology, Vol. 57, Iss. 3, 1999-10 ,pp. : 202-210

Karger

Access to resources Recommend Favorite

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

By  

Oncology, Vol. 90, Iss. 1, 2016-0 ,pp. : 21-28

Karger

Access to resources Recommend Favorite

A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 38-45

Karger

Access to resources Recommend Favorite

Phase II Study with Gemcitabine in Gallbladder and Biliary Tract Carcinomasa

By  

Oncology Research and Treatment, Vol. 21, Iss. 3, 1998-07 ,pp. : 232-234

Karger

Access to resources Recommend Favorite